Hypersomnia Treatment Market By Product Type (Oxybates, Wake-Promoting Agents, Central Nervous System Stimulants, Histamine H3 Receptor Antagonists/Inverse Agonists, Orexin Receptor Agonists, Other Pharmacological Treatments); By Application (Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Other Hypersomnia Disorders); By End User (Hospitals, Sleep Clinics and Sleep Centers, Neurology Clinics, Specialty Clinics, Homecare Settings); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hypersomnia Treatment Market: Diagnosis Delays, Franchise Expansion, and Orexin Competition Reshape Revenue

The Global Hypersomnia Treatment Market was valued at USD 3.42 billion in 2025 and is projected to reach USD 5.41 billion by 2032, growing at a CAGR of 6.8%, according to Strategic Market Research.

 

Public disclosures show that hypersomnia treatment has become a substantial specialty-pharmaceutical category, particularly in the United States. Harmony Biosciences estimates that the U.S. narcolepsy market generated approximately USD 3.1 billion in net sales in 2025. Jazz Pharmaceuticals reported USD 1.657 billion in Xywav sales, Harmony’s WAKIX generated USD 868.5 million, and LUMRYZ recorded approximately USD 279.1 million.

 

The company figures cannot be added into a precise market total. Several products cover more than one indication, patients may use multiple medicines, and company-reported patient counts can overlap. Product revenue, diagnosed-population estimates, reimbursement position, and specialist access provide a more reliable view of competitive development than combined brand sales alone.

 

Diagnosis Delays Restrict Patient Conversion

Long diagnostic pathways remain the largest barrier to treatment volume. A 2025 study reported median diagnostic delays of about four years for narcolepsy type 1, five years for narcolepsy type 2, and eight years for idiopathic hypersomnia. Patients who do not reach a specialist sleep centre remain outside prior-authorization systems, specialty-pharmacy programs, and long-term branded treatment.

Harmony estimates that around 80,000 people in the United States have idiopathic hypersomnia, with approximately 40,000 diagnosed. Jazz reported about 5,225 active Xywav patients with idiopathic hypersomnia at the end of 2025. The difference is not a directly available treatment pool because diagnosed patients may use generic stimulants, receive off-label therapy, remain untreated, or discontinue medication. Current branded treatment nevertheless reaches only part of the diagnosed population.

Diagnosis rates matter more commercially than headline prevalence. Prescription growth depends on specialist confirmation, documented eligibility, payer approval, and treatment persistence. Manufacturers therefore invest in physician education, referral support, and patient identification alongside conventional promotion.

Functional burden also influences reimbursement and prescribing decisions. Participants in the Real World Idiopathic Hypersomnia Outcomes Study reported mean impairment of 51.4% in overall work productivity and 64.0% in regular daily activities. Evidence that treatment improves daily functioning, work participation, and sustained alertness can carry more commercial weight than improvement on a single sleepiness scale.

 

Oxybates Hold the Largest Disclosed Revenue Position

Oxybate products account for the largest publicly disclosed revenue in hypersomnia treatment. Xywav generated USD 1.657 billion in 2025 and had approximately 16,175 active patients at year-end, including 10,950 with narcolepsy and 5,225 with idiopathic hypersomnia. Jazz benefits from established specialist relationships, payer support, controlled distribution, and patient-service infrastructure built around the franchise.

Xywav remains the only established FDA-approved branded treatment for adults with idiopathic hypersomnia. Orphan-drug exclusivity continues through August 12, 2028, giving Jazz time to expand the treated population and strengthen payer coverage before direct indication-level competition arrives.

Generic and authorized-generic versions of high-sodium oxybate have reduced the value of the older Xyrem brand. Revenue is moving toward newer protected formulations and indications, while legacy products face stronger pricing and share pressure.

LUMRYZ has shown that a newer oxybate brand can gain meaningful revenue despite an established incumbent. Sales increased from approximately USD 169.1 million in 2024 to USD 279.1 million in 2025, and the treated-patient base reached about 3,400 by September 2025. Adoption has come from focused specialist promotion and differentiation within the narcolepsy market.

Alkermes completed its acquisition of Avadel Pharmaceuticals in February 2026, gaining LUMRYZ, a sleep-medicine sales organization, and specialty-pharmacy relationships. The transaction gives Alkermes immediate revenue and a commercial platform for future sleep-wake products rather than leaving the company dependent on unapproved pipeline assets.

 

Idiopathic Hypersomnia Is Becoming a Distinct Competitive Segment

Idiopathic hypersomnia is moving away from an off-label treatment market toward a separate branded category. Xywav established regulatory and reimbursement precedent, while newer programs are targeting diagnosed patients who remain outside its current base.

Alkermes reported positive topline results from the Phase 3 REVITALYZ study of LUMRYZ in adults with idiopathic hypersomnia in May 2026. A successful filing could create the first direct branded oxybate competitor to Xywav in the indication.

LUMRYZ would enter with an existing narcolepsy prescriber base and specialty-distribution network, lowering the incremental cost of an idiopathic hypersomnia launch. Alkermes could target newly diagnosed patients, people receiving off-label treatment, and selected patients who remain dissatisfied with current therapy.

Jazz still holds major commercial advantages through Xywav’s established patient base, payer contracts, treatment experience, and orphan exclusivity. Competition would initially centre on new patient starts, formulary positioning, and physician preference rather than large-scale switching.

Harmony Biosciences also pursued idiopathic hypersomnia with pitolisant. Its initial Phase 3 program did not support a successful filing, and the FDA issued a refusal-to-file response in February 2025. Harmony is continuing development through Pitolisant HD. The setback reinforces the difficulty of converting unmet need into an approvable label and preserves Xywav’s position for longer.

 

WAKIX Supports a Large Non-Oxybate Franchise

WAKIX generated USD 868.5 million in 2025 and served an average of approximately 8,500 patients during the fourth quarter. Harmony also reported access across more than 80% of U.S. insured lives.

Substantial revenue therefore exists outside oxybates. WAKIX benefits from specialist familiarity, payer coverage, and use among patients who may not be suitable for or willing to enter restricted oxybate-distribution systems.

Combination treatment is common in narcolepsy because physicians often address several clinical problems in the same patient. Multiple prescriptions can expand revenue for differentiated products, but overlapping use prevents product-level patient counts from being summed into a unique treated population.

WAKIX also gives Harmony a ready commercial platform for higher-dose pitolisant and future sleep-wake therapies. Existing relationships with specialists and payers reduce the cost and execution risk of launching another product into the same treatment network.

 

Orexin Agonists Could Alter Treatment Sequencing

Orexin receptor agonists are the most consequential pipeline development because they may change the position of existing medicines rather than simply add another wake-promoting option.

Takeda’s oveporexton, previously known as TAK-861, is the nearest major regulatory catalyst. The FDA accepted its application for narcolepsy type 1 and granted Priority Review in February 2026, with a target action date in the third quarter of 2026. As of July 13, 2026, the product remained investigational.

Approval would give physicians a new option for narcolepsy type 1 and could affect demand across oxybates, WAKIX, stimulants, and combination regimens. Adoption will depend on pricing, payer restrictions, safety, persistence, and whether physicians believe the medicine can reduce reliance on several concurrent treatments.

Takeda also has submissions under review in Japan and China. Approval across several major markets could establish orexin-based treatment as a global commercial category rather than a single-country launch.

Alkermes is developing alixorexton for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. Phase 3 Brilliance studies are underway in narcolepsy, and the company continues development in idiopathic hypersomnia. Breakthrough Therapy designation for narcolepsy type 1 and Orphan Drug designation for idiopathic hypersomnia support regulatory engagement but do not remove late-stage development risk.

Ownership of both LUMRYZ and alixorexton gives Alkermes exposure to the current oxybate market and a possible future orexin shift. The company can position products across different patient groups if both programs succeed.

Axsome Therapeutics is developing AXS-12 for narcolepsy while commercializing Sunosi. Sunosi generated USD 120.1 million in 2025, up from USD 90.3 million in 2024, although revenue includes both narcolepsy and obstructive sleep apnea.

Zevra Therapeutics’ KP1077 remains an earlier-stage idiopathic hypersomnia opportunity, with no active Phase 3 program publicly confirmed through July 2026. Its commercial timing remains less certain than LUMRYZ expansion, oveporexton, or alixorexton.

 

Payer Access Determines Revenue Conversion

The U.S. market is concentrated among a relatively small specialist community. Harmony estimates that about 9,000 healthcare professionals treat narcolepsy, while around 4,000 are enrolled in oxybate risk-management programs.

A concentrated prescriber base allows companies to use focused specialist sales teams, but it also intensifies competition for the same physicians. Established suppliers benefit from long-standing clinical relationships, reimbursement staff, and patient-support systems.

Oxybate products require controlled distribution and additional administrative steps. Prescribers and patients must complete enrollment requirements, and dispensing occurs through specialist channels rather than normal retail pharmacies. Authorization delays can lead to abandoned starts, making reimbursement support and bridge programs commercially important.

LUMRYZ distribution is highly concentrated. Caremark, Accredo, and Optum accounted for all reported gross sales in 2025. Dependence on three specialty-pharmacy organizations gives those accounts significant operational and contracting influence.

Insurance coverage does not guarantee conversion. Payers may require specialist confirmation, diagnostic records, previous-treatment history, and enrollment in safety programs. Copay support, temporary supply, free-drug programs, and authorization assistance have become part of the operating cost of branded hypersomnia treatment.

 

North America Leads, While Europe Remains Reimbursement-Led

North America, particularly the United States, holds the strongest identifiable market position. High branded-product revenue, specialist prescribing, commercial insurance, controlled distribution, and patient-support infrastructure allow suppliers to sustain premium franchises.

Alkermes has cited more than 50,000 oxybate-eligible U.S. narcolepsy patients. The available commercial population is smaller after accounting for payer eligibility, existing treatment satisfaction, physician preference, and patient willingness to use restricted products, but the estimate still indicates room for continued patient acquisition.

European markets contain meaningful patient populations but provide less unrestricted access to premium brands. The NHS estimates that about 30,000 people in the United Kingdom have narcolepsy. NICE positions solriamfetol after modafinil and either dexamfetamine or methylphenidate have proved inadequate or unsuitable, narrowing the eligible population at launch.

France’s public assessment estimated approximately 18,800 adults with narcolepsy, around 3,760 diagnosed patients, and a maximum later-line solriamfetol population of about 1,880. Germany’s public reimbursement documentation estimated approximately 20,347 adults with narcolepsy. Diagnosis, specialist referral, reimbursement position, and treatment sequence reduce the population available to individual brands well below headline prevalence.

Comparable indication-level revenue data are not publicly available for most Asia-Pacific countries. Takeda’s oveporexton submissions in Japan and China provide the clearest regional investment signal, but regulatory filings do not confirm near-term revenue at U.S. levels.

 

Competitive Outlook

Jazz Pharmaceuticals remains the commercial leader through Xywav, its large treated-patient base, established idiopathic hypersomnia position, and specialty-access infrastructure.

Harmony Biosciences holds the strongest disclosed non-oxybate franchise through WAKIX. Continued patient and revenue growth support further development, although the earlier idiopathic hypersomnia setback remains relevant.

Alkermes has become the main integrated challenger after acquiring Avadel. LUMRYZ provides current revenue, REVITALYZ creates a potential idiopathic hypersomnia expansion, and alixorexton gives the company exposure to an orexin-led market shift.

Takeda is the most important near-term potential entrant. An oveporexton approval could change treatment sequencing in narcolepsy type 1 and increase pressure on established drug classes.

Near-term revenue growth will come from additional Xywav, WAKIX, and LUMRYZ patients, possible LUMRYZ expansion into idiopathic hypersomnia, and potential oveporexton entry. Longer-term competition will depend on whether orexin agonists gain payer coverage, retain patients, and reduce multi-drug treatment.

Diagnosis remains the main volume constraint. Forecasts based on prevalence without adjusting for specialist confirmation, reimbursement eligibility, persistence, and access restrictions are likely to overstate the available market. Regulatory failure, generic erosion, patent disputes, specialty-pharmacy concentration, payer restrictions, and uncertain switching behaviour remain the principal commercial risks.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 3.42 Billion
Revenue Forecast in 2032	USD 5.41 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Distribution Channel, By Geography
By Product Type	Oxybates, Wake-Promoting Agents, Central Nervous System Stimulants, Histamine H3 Receptor Antagonists/Inverse Agonists, Orexin Receptor Agonists, Other Pharmacological Treatments
By Application	Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia, Other Hypersomnia Disorders
By End User	Hospitals, Sleep Clinics and Sleep Centers, Neurology Clinics, Specialty Clinics, Homecare Settings
By Distribution Channel	Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising diagnosis of narcolepsy and idiopathic hypersomnia, expanding access to oxybate and wake-promoting therapies, stronger sleep-clinic referral networks, growing specialty pharmacy support, and advancing orexin-based treatment pipelines
Customization Option	Available upon request